Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Metastatic Adrenocortical Carcinoma
NCT02720484Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in adrenocortical carcinoma (ACC), sponsored by Northwestern University. Started Mar 2016; status: terminated.
02
Drugs
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT02720484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720484.